Rocket Pharmaceuticals Warrant
RCKTW
12 hedge funds and large institutions have $161K invested in Rocket Pharmaceuticals Warrant in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 5 reducing their positions, and 1 closing their positions.
0.13% less ownership
Funds ownership: 2.12% → 1.99% (-0.13%)
8% less funds holding
Funds holding: 13 → 12 (-1)
54% less capital invested
Capital invested by funds: $349K → $161K (-$188K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.22K |
| 2 |
Walleye Capital
New York
|
-$962 |
| 3 |
Walleye Trading
New York
|
-$857 |
| 4 |
VF
Virtu Financial
New York
|
-$301 |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$102 |
RCKTW Hedge Fund Activity: Q2 2025 in Review
12 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals Warrant (RCKTW) for Q2 2025, worth a combined $161K — down 54% from $349K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RCKTW and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, cutting an estimated $3.22K.
- 12 institutional investors held Rocket Pharmaceuticals Warrant (RCKTW) as of Q2 2025, down from 13 in Q1 2025.
- Funds reported $161K of Rocket Pharmaceuticals Warrant stock for Q2 2025, down 54% quarter-over-quarter.
- 0 funds opened new Rocket Pharmaceuticals Warrant positions in Q2 2025 and 1 closed out, a net change of -1 holder.
- The largest Rocket Pharmaceuticals Warrant seller in Q2 2025 was Susquehanna International Group, an estimated $3.22K sold.
Based on aggregated 13F filings for Q2 2025.